PTYLTD
    • Free Reports
  • Pricing
  • About us
  • Contact us
  • Login | Sign up
PTYLTD

Free Reports

Pricing

About us

Contact us

  • Home
  • Insights into ASX Stocks

Insights into ASX Stocks

Collins Foods (ASX: CKF)

Collins Foods (ASX: CKF) - Why We Think CKF Is Entering Its Strongest Earnings Cycle Since Pre-COVID

Dec 30, 2025
Proactive Equities Team

We believe Collins Foods (ASX: CKF) is entering a multi-year earnings recovery cycle anchored by margin repair in Australia, operational rejuvenation in Europe, clear line-of-sight to double-digit EBITDA growth, and an improving balance sheet that gives management options rather than constraints. The HY26 results demonstrate that CKF is moving decisively out of the inflation shock period that suppressed margins and elevated operating costs between 2022–2024. With commodity and utilities inflation easing, labour efficiencies improving, and price/mix still resilient, we see structural tailwinds forming beneath the company’s operating base.

silver prices soaring and how to benefit on asx

Why silver prices keep soaring, and how you can benefit from it on the ASX?

Dec 30, 2025
Proactive Equities Team

Silver has quietly moved into a powerful uptrend, and it’s not happening by accident. The metal is being pulled in two directions at once, as a financial haven and as an industrial workhorse. For ASX investors, this creates an opportunity. Exposure comes through producers, developers, and explorers whose revenues and valuations tend to rise as silver prices strengthen, offering leverage to a market driven by both fear and future-focused demand.

Commonwealth Bank of Australia (ASX: CBA)

Commonwealth Bank of Australia (ASX: CBA) - Why We See Structural Strength in Australia’s Premium Bank

Dec 29, 2025
Proactive Equities Team

Commonwealth Bank of Australia (ASX: CBA) remains the undisputed heavyweight of the Australian financial system, dominant in retail banking, advantaged by scale, and well-positioned to monetise the next phase of household re-leveraging as rates peak and credit growth stabilises. Our view is simple: CBA’s franchise resilience is undervalued. While the macro backdrop remains mixed and competition in mortgages remains intense, the bank continues to deliver sector-leading returns, defend margin leadership, and maintain one of the strongest balance sheets globally.

LaserBond (ASX: LBL)

LaserBond (ASX: LBL)- Engineered for Investors Seeking Durable Industrial Growth Exposure

Dec 19, 2025
Proactive Equities Team

LaserBond (ASX: LBL) has entered a structurally stronger period after FY25 delivered clear evidence of operating leverage, improved manufacturing efficiencies, and accelerating adoption of its surface-engineered technologies across mining, energy, defence, and agricultural markets. With its patented LaserBond® cladding and composite coating systems now demonstrating superior lifecycle economics versus traditional wear-resistance methods, the company is positioned as a high-margin engineering solutions provider rather than a cyclical industrial.

Sunrise Energy Metals (ASX: SRL)

Sunrise Energy Metals (ASX: SRL) - Positioned at the Strategic Heart of Western Critical Minerals Supply Chains

Dec 11, 2025
Proactive Equities Team

Sunrise Energy Metals (ASX: SRL) is advancing one of the Western world’s most strategically significant battery-materials developments: the Sunrise Nickel-Cobalt-Scandium Project in NSW, a globally large, long-life, ESG-aligned source of critical minerals essential for EVs, aerospace alloys, defence technologies and high-performance fuel cells. Backed by strong balance sheet discipline, rising government engagement, escalating Western supply-security policies, and material advancement across strategic partnerships during 2025, Sunrise enters 2026 with a profile we view as deeply undervalued relative to its strategic optionality.

Recce

How Much Higher Can Recce Pharmaceuticals' (ASX: RCE) Share Price Go After the Recent Breakout?

Dec 8, 2025
Proactive Equities Team

Recce has recently attracted attention because it’s advancing drug candidates against serious infections, a space with significant potential if late-stage trials succeed. That kind of promise is why some market watchers see upside in RCE’s shares. On the flip side, the company remains unprofitable, with no consistent earnings or predictable cash flow, so it’s still a speculative biotech rather than a stable performer.

 

Proactive Equities

At Proactive Equities, we combine deep market expertise with rigorous analysis to deliver stock recommendations you can trust. Our team of seasoned analysts continuously monitor global markets, economic trends, and company fundamentals to identify high-potential investment and trade opportunities.

Company

Home
Pricing
Contact Us
About Us

Resources

ASX Insights
Investing Basics

Links

Privacy Policy
Terms and Conditions
Product Disclosure Statement

Proactive Equities Pty Ltd (ACN: 687 232 471) is a Corporate Authorised Representative (AFSR No. 001318293) of Australia National Investment Group Pty Ltd (ABN: 40 636 343 630), which holds an Australian Financial Services Licence (AFSL no. 522028). The information on this website is general information only and does not constitute personal financial advice. We have not taken the individual circumstances, financial objectives or needs of any investor into account when preparing this information. Investors should consider their circumstances and the relevant PDS for any investment and obtain professional financial and tax advice before making any investment decision. The information on this website is not a recommendation to make any investment or to adopt any particular investment strategy. You should make your own professional assessment of the suitability of this information, relying on your own inquiries. Investments in securities are subject to investment risk. Investment value may go down as wellas up, and investors may not get back the full amount originally invested. Risks include: the investment objective may not be achieved, share market and other market risk, liquidity risk, and currency risk with international investments. Any past performance shown is not an indication of future performance. Commission and other costs charged by executing broker are not considered when calculating past performance. To the extent permitted by law Proactive Equities Pty Ltd accepts no liability for any errors or omissions in, or loss from reliance on the information in this website.

1...192021...25
Page 20 of 25